Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics
VTYX Price/Volume Stats
| Current price | $2.02 | 52-week high | $11.48 |
| Prev. close | $1.89 | 52-week low | $1.67 |
| Day low | $1.83 | Volume | 2,278,800 |
| Day high | $2.04 | Avg. volume | 2,006,136 |
| 50-day MA | $2.26 | Dividend yield | N/A |
| 200-day MA | $2.83 | Market Cap | 142.84M |
VTYX Stock Price Chart Interactive Chart >
Ventyx Biosciences, Inc. (VTYX) Company Bio
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
VTYX Price Returns
| 1-mo | -9.82% |
| 3-mo | -8.60% |
| 6-mo | -30.34% |
| 1-year | -0.49% |
| 3-year | -86.40% |
| 5-year | N/A |
| YTD | -7.76% |
| 2024 | -11.34% |
| 2023 | -92.47% |
| 2022 | 65.11% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...